---
document_datetime: 2023-09-21 19:46:24
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/atryn-epar-procedural-steps-taken-authorisation_en.pdf
document_name: atryn-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5515419
conversion_datetime: 2025-12-15 02:24:19.983433
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Genzyme  Europe  B.V.  submitted  on  23  January  2004  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  ATryn,  through  the  centralised procedure.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

<!-- image -->

Rapporteur: E. Abadie Co-Rapporteur:   I.Hudson Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The application was received by the EMEA on 23 January 2004. · The procedure started on 23 February 2004. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 5 May 2004. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 4 May 2004. · During the meeting on 9-11 June 2004, the BWP adopted a first report to the CHMP. · During  the  meeting  on  22-24  June  2004,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  24 June 2004. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 03 December 2004. · The summary reports of the first and second inspection carried out at the site in Cambrex Bio Science in Massachusetts between 9-11 August 2005 and 12-14 December 2005 were issued on 02 December 2005 and 31 January 2006. · The  summary  report  of  the  inspection  carried  out  at  the  GTC  Biotherapeutics  Farm  in Massachusetts between 8-9 August 2005 was issued on 7 December 2005. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  14 February 2005. · During  their  meeting  of  8-9  March  2005,  the  BWP  discussed  the  major  outstanding  quality questions and adopted a second report to the CHMP. · During the CHMP meeting on 14-17 March 2005, the CHMP agreed on a list of outstanding issues to be addressed in writing and during an oral explanation before the CHMP. · The applicant submitted the written responses to the list of outstanding issues on 8 July 2005. · During  their  meeting  of  7-9  November  2005,  the  BWP  discussed  the  responses  to  the outstanding quality questions and adopted a third report to the CHMP. The Rapporteur circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding issues to all CHMP members on 27 January 2006. During the CHMP meeting on 20-23 February 2006, outstanding issues were addressed by the applicant during an oral explanation before the CHMP. Medicinal product no longer authorised

- During  the  meeting  on    20-23  February  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  negative  opinion  for granting a Marketing Authorisation to ATryn on 22 February 2006.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 3. Steps taken for the re-examination procedure

- The applicant received the CHMP opinion on 24 February 2006
- The  applicant  submitted  written  notice  to  the  EMEA  on  2  March  2006  to  request  a  reexamination of the ATryn CHMP opinion of 22 February 2006.
- During  its  meeting  on  20-23  March  2006,  the  CHMP  appointed  Dr  Bengt  Ljungberg  as Rapporteur and Dr Gonzalo Calvo Rojas as Co-Rapporteur for the re-examination procedure.
- The  detailed  grounds  for  the  re-examination  request  were  submitted  by  the  applicant  on 24 April 2006. The re-examination procedure started on 25 April 2006.
- The Rapporteur's Assessment Report was circulated to all CHMP members on 9 May 2006. The Co-Rapporteur's Assessment Report was circulated to all CHMP members on 10 May 2006. · An Ad hoc Expert Group meeting on ATryn was held on 29 May 2006 at the EMEA. During this meeting the applicant presented an oral explanation. A report of this meeting was forwarded to CHMP. · During the CHMP meeting on 30 May 2006 to 1 June 2006, the applicant presented an oral explanation before the CHMP on the 30 May 2006. · During the meeting on 30 May 2006 to 1 June 2006, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee,  issued a final Opinion recommending the granting of the Marketing Authorisation under exceptional circumstances to ATryn on 1 June 2006. · The  CHMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decision on 28 July 2006. Medicinal product no longer authorised

<!-- image -->